Pulmonx Corp. (LUNG): Price and Financial Metrics


Pulmonx Corp. (LUNG): $44.36

-0.27 (-0.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

LUNG Stock Price Chart Interactive Chart >

Price chart for LUNG

LUNG Price/Volume Stats

Current price $44.36 52-week high $69.48
Prev. close $44.63 52-week low $35.81
Day low $43.86 Volume 274,600
Day high $44.91 Avg. volume 333,605
50-day MA $43.48 Dividend yield N/A
200-day MA $0.00 Market Cap 1.61B

Pulmonx Corp. (LUNG) Company Bio


Pulmonx Corp. provides interventional pulmonology, planning tools, and treatments for obstructive lung diseases. It carries out its operations in the following geographical locations: Europe, Middle East and Africa (EMEA), Asia Pacific, Other International, and United States. It offers the Zephyr Endobronchial Valve, an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema. It also offers StratX Lung Analysis, a platform designed to treat severe emphysema, and the Chartis Assessment System, a pulmonary assessment system. The company was founded by Rodney C. Perkins and is headquartered in Redwood City, CA.


LUNG Latest News Stream


Event/Time News Detail
Loading, please wait...

LUNG Latest Social Stream


Loading social stream, please wait...

View Full LUNG Social Stream

Latest LUNG News From Around the Web

Below are the latest news stories about Pulmonx Corp that investors may wish to consider to help them evaluate LUNG as an investment opportunity.

Zephyr® Valve Treatment Provides Long-Term Quality of Life and Lung Function Improvements for Patients with Severe COPD/Emphysema

New Data Presented at ATS 2021 International Conference Shows Positive, Sustained Benefits to Patients Treated with this First Minimally Invasive, Non-drug Treatment OptionREDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced that key long-term follow-up data from the TRANSFORM® study was presented at the American Thoracic Society (ATS) virtual 2021 International Conference. The new data confirm the long-term benefits of the Zephyr® Endobronchial Valve (Zephyr Valve), the first minimally invasive procedure to treat patients with severe COPD/emphysema. The study shows that the Zephyr Valves provide significant benefits to patients including improvements ove...

Yahoo | May 17, 2021

Pulmonx Corporation 2021 Q1 - Results - Earnings Call Presentation

The following slide deck was published by Pulmonx Corporation in conjunction with their 2021 Q1 earnings call....

SA Transcripts on Seeking Alpha | May 13, 2021

Pulmonx Corporation (NASDAQ:LUNG) Released Earnings Last Week And Analysts Lifted Their Price Target To US$60.14

Pulmonx Corporation ( NASDAQ:LUNG ) defied analyst predictions to release its first-quarter results, which were ahead...

Yahoo | May 7, 2021

Pulmonx Reports First Quarter 2021 Financial Results

REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the first quarter ended March 31, 2021. Recent Highlights Reported worldwide revenue of $9.2 million in the first quarter of 2021, a 7% increase over the same period last yearAchieved gross margin of 71.5% in the first quarter of 2021 as compared to 65.6% in the same period last yearIncreased number of U.S. Zephyr Valve treating centers from 148 to 160Expanded U.S. sales management team from 6 to 9 regional directors while increasing total number of U.S. sales territory managers from 45 to 51Experienced a recovery in U.S. procedures in March as hospital constr...

Yahoo | May 4, 2021

Pulmonx Corporation Expands Leadership Team

REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the appointment of Michael Ryan as Vice President, Corporate Strategy and Business Development, and the earlier appointments of David Lehman as General Counsel, and Mahtab Fatemi as Vice President, Regulatory Affairs and Quality Assurance. “We could not be more excited to have these three deeply experienced professionals on the Pulmonx team. Each of these individuals is uniquely qualified and brings a wealth of insight and knowledge about the medical device business to their respective areas of responsibility,” said Glen French, President and CEO of Pulmonx. Mr. Ryan, who will lead all corporate st...

Yahoo | May 4, 2021

Read More 'LUNG' Stories Here

LUNG Price Returns

1-mo 16.68%
3-mo -26.60%
6-mo -4.75%
1-year N/A
3-year N/A
5-year N/A
YTD -35.73%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6694 seconds.